Analysts' Actions: Halozyme, Hewlett-Packard, Immunogen, Sprouts

NEW YORK (TheStreet) -- RATINGS CHANGES

Halozyme Therapeutics (HALO) was upgraded at UBS to buy from neutral, UBS said. Driven on pipeline potential and undervalued valuation, UBS said. Twelve-month price target is $16.

Hewlett-Packard (HPQ) was upgraded at Goldman Sachs to neutral from sell. Management has executed far more effectively than anticipated, Goldman Sachs said. Twelve-month price target is $32.

Immunogen (IMGN) was upgraded at UBS to neutral from sell. Bullish outlook on Kadcyla and royalty revenue providing lower-risk valuation support, UBS said. Twelve-month price target is $13.

Points International (PCOM) was downgraded to hold at TheStreet Ratings.

Phoenix Companies (PNX) was upgraded to hold at TheStreet Ratings.

Springleaf (LEAF) was downgraded at Sterne Agee to neutral. Twelve-month price target is $28. Estimates were also cut, because of weakness in two units, Sterne Agee said.

Sprouts (SFM) was upgraded at Credit Suisse to outperform from neutral. Twelve-month price target is $34. Pullback provides an opportunity, Credit Suisse said. Twelve-month price target is $34.

Triumph (TGI) was upgraded at Credit Suisse to outperform from neutral. Company offers growth at a reasonable price, Credit Suisse said. Twelve-month price target is $88.

Theravance (THRX) was downgraded at Robert Baird to hold from buy. Valuation call, following the recent split, Robert Baird said.

If you liked this article you might like

Hewlett Packard Enterprise's Meg Whitman Joins Dropbox

Carly Fiorina Will Not Run for Senate in 2018

Carly Fiorina on Not Running for Senate, Cryptocurrency and the Opioid Epidemic

Hewlett Packard Enterprise Jumps After-Hours on Q3 Earnings Beat

HPE's Meg Whitman Will Have to Answer Some Tough Questions on Tuesday